Form 8-K · Current Report · Filed 2024-08-08
Gilead Reports 5% Revenue Growth in Q2 2024, Reiterates Full-Year Guidance
Gilead Sciences, Inc. reported a 5% increase in total second quarter 2024 revenue to $7.0 billion, driven by higher product sales in HIV, Liver Disease, and Oncology. Diluted earnings per share (EPS) was $1.29, up from $0.83 in the same period of 2023. The company repurchased $100 million of common stock and paid dividends of $972 million. Gilead also presented detailed product sales figures and guidance for the full year 2024.
- Filer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Accession
- 0000882095-24-000020
- CIK
- 0000882095
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$74.00
Next session
-0.5%
Since filing
+76.0%
Latest close
$130.21
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GILD reporting the same item, with the next session's move:
Exhibits (1)
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Never miss another GILD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.